Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 05 October 2012 | By Louise Zornoza,
Brazil's national regulatory authority, Anvisa, announced on 4 October a number of steps it has implemented to address the priority public health needs of the country, part of a multi-year reorganization aimed at better addressing the health and economic development needs of the country and its population.
One of the measures it has implemented is the establishment of an expedited review and approval procedure for medicines deemed to be priority treatments for use by the national health service (SUS). Drugs eligible for the expedited procedure include generics as well as innovative new drugs.
Another measure is its review of its regulatory framework. It said it has made a number of changes where necessary, including simplifying the registration process and entering into information exchange agreements on manufacturing site inspections with counterpart regulatory agencies in a number of countries, such as Argentina, Australia, Canada, France, the UK and the US.
The agency is also in the process of implementing an electronic application filing process, due to launch later this year, which will further speed up product reviews.
Anvisa also provided a review of its achievements over the last three years. Between 2009 and 2012, it said, 214 applications for registration of new molecules were filed with Anvisa. Of these, 87% have been reviewed by the agency and 62% (133 requests) have had a final determination (acceptance, rejection or termination of proceedings on request) issued by the agency. Twenty-five percent (54 requests) are currently under review, while only 13% (27 applications ) are awaiting the initiation of review. The oldest application without response from Anvisa was filed in March of this year.
Read more:
Read all Breaking News from RegLink
Tags: Drug Approval, Priorities, Latest News, brazil, review, regulations
Regulatory Focus newsletters
All the biggest regulatory news and happenings.